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Abstract
Background: ePrescribing systems have considerable potential for improving healthcare quality and safety. With growing
expectations about the benefits of such systems, there is evidence of widespread plans to implement these systems in
hospitals in England where hitherto they have had a low uptake. Given the international drive away from developing home-
grown to systems to procuring commercial applications, we aimed to identify available ePrescribing systems in England and
to use the findings to develop a taxonomy of the systems offered by suppliers.
Methods and Findings: We undertook a scoping review of the published and grey literature, and conducted expert
interviews with vendors, healthcare organisations and national ePrescribing experts in order to identify the spectrum of
available systems, identify and map their key features, and then iteratively develop and validate a taxonomy of commercial
ePrescribing systems available to English hospitals. There is a wide range of available systems including 13 hospital-wide
applications and a range of specialty systems. These commercial applications can be grouped into four sub-categories:
standalone systems, modules within integrated systems, functionalities spread over several modules, and specialty systems.
The findings also reveal that apart from four packaged applications (two of which are specialty systems), all other systems
have none or less than two live implementations across England.
Conclusions: The wide range of products developed in the last few years by different national and international suppliers,
and the low uptake of these products by English hospitals indicate that the English ePrescribing market is still in its infancy.
This market is undergoing rapid cycles of change, both with respect to the number of suppliers and their diversity of
offerings. Constant renewal of knowledge is needed on the status of this evolving market, encompassing the products
development and adoption, to assist implementation decisions and facilitate market maturity.
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Introduction
The literature on hospital electronic prescribing (henceforth,
ePrescribing) systems reveal the importance of these software
applications in helping to enhance patient safety and to improve
the quality and efficiency of healthcare [1–4]. The main
demonstrated benefits of implementing ePrescribing systems
include reduction of duplicate prescribing, dosing errors and
issuing of and issuing of, contraindicated drugs, and enhancing
adherence with formulary recommendations [2,4–10]. With
growing appreciation of these potential benefits, there is
widespread plans to implement these systems into to hospitals in
England where hitherto they have had little uptake [11–12].
Whilst earlier research on ePrescribing has focused on ‘home
grown’ applications that have been internally developed by local
teams [13], more recently the focus has shifted to implementing
commercial of-the-shelf or ‘packaged’ ePrescribing systems [14–
15]. These are diverse in terms of their functionality and
complexity, ranging from basic data entry systems to more
sophisticated applications providing medicines administration and
decision support functionalities. Given the considerable work and
resources involved in implementing these systems [16], it is
therefore surprising that there is currently no comprehensive
overview of the ePrescribing systems potentially available to
National Health System (NHS) hospitals in England or indeed the
key properties of these systems.
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Technology suppliers have responded to growing expectations
about ePrescribing benefits and policies encouraging their uptake
by NHS hospitals. A wide and increasing range of providers are
thus now offering their solutions to hospitals. Deciding on which
system to procure is an important and costly decision with long-
term consequences for the healthcare organisation concerned and
possibly also for patient outcomes [16–17]. Given this situation, we
sought to build on our national descriptive studies of planned
implementations of ePrescribing systems [6,12] and embarked
upon a study of the current state of ePrescribing offerings available
and, in some cases, in use in secondary care in England. Our
earlier questionnaire study showed that while only 7% of English
hospitals were using an ePrescribing system, 20% of hospitals were
implementing and 55% were in the process of planning or
procuring a system [6]. This work extends that study by aiming to
provide an overview of the current ePrescribing market in England
and develop a taxonomy of the systems offered by the increasing
number of suppliers in this expanding market. We also sought to
draw attention to the possible impacts of this diversity on decision
making for uptake of ePrescribing applications.
Materials and Methods
Ethical Considerations
This study is a part of a national research programme
investigating the implementation and adoption of ePrescribing
systems in English hospitals, which received ethical approval from
The University of Edinburgh’s Research Ethics Committee. We
also received guidance on 6 August 2012 from the NHS Health
Research Authority NRES Committee London City and East that
the study did not require review from an NHS ethics committee.
The data obtained for this work comprised of publicly available
documents and participants who had given their written informed
consent to participate and be interviewed. Interview data were
anonymised for analysis.
Overview of Research Methods
We used a mixed-method approach that involved discussion
with experts, a scoping review of the literature and in-depth
qualitative expert interviews. In order to help ground this work
within the context of NHS England we used NHS Connecting for
Health’s working definition of ePrescribing systems [15]:
‘The utilisation of electronic systems to facilitate and
enhance the communication of a prescription or medicine
order, aiding the choice, administration and supply of a
medicine through knowledge and decision support and
providing a robust audit trail for the entire medicines use
process’.
Data Generation and Analysis. Data generation and
analysis for this study were performed concurrently in four stages
as described below.
The first stage of data collection involved interviews with a
network of recognised experts from NHS professional domains
with the purpose of refining a baseline definition for the inclusion
of applications as ePrescribing systems. This network consisted of
members of NHS who had closely worked with and studied
ePrescribing systems in England. In these interviews we asked the
interviewees about what should be considered as ePrescribing
system. The results were analysed in terms of UK terms for
ePrescribing systems and hospitals. This resulted in the identifi-
cation of search criteria for document searching shown in Table 1.
In the second stage of data collection, which gathered the main
body of data for this study, we collected documents mainly from
online sources and healthcare conferences. A summary of data
sources types is shown in Table 2. In this stage, with the help of the
research team and the study librarian we initially examined our
internal programme library (collected by members of our research
team over the last three years) for any documents previously
collected from a range of healthcare conferences. These confer-
ences were either those organised by our research team (such as
‘ePrescribing: everything you want to know but were afraid to ask!
A symposium for the health service’ held in March 2013), or those
attended by the programme team (such as ‘Electronic Prescribing
in Hospitals: Moving Forward’ held on February 2012). Data
sources from these conferences included suppliers’ commercial
materials, presentation slides, reports and papers publically
distributed in conferences. This formed a provisional picture of
the market, which was used as an initiating point for the document
search process. In the document search process we used the search
criteria (using a combination of keywords in column 1 and column
2 of Table 1 obtained from stage one) to find any online
information available on suppliers of ePrescribing systems in
England. This resulted in discovering four main sources of online
documents for further examination: suppliers’ commercial web-
sites, NHS websites (including NHS hospitals and NHS Connect-
ing for Health), academic journals, and online media (particularly
E-Health Insider - EHI). These documents were analysed further
to gather data on the state/progress of adoption of systems in
English hospitals. This was done through examining data obtained
from several data sources [18]. We started this by examination of
the information available in each of these websites and their
subordinate webpages. To do this we initially developed a table
consisting of the suppliers and products details. Data for this table
was initially generated from suppliers’ websites. Then this data was
checked against data obtained from NHS webpages and online
media. This led to more in depth data for each of the suppliers/
products in the list. It also led to discovery of some new
ePrescribing products/suppliers in operation in England to be
added to the list. These new data were once more checked with
data from supplier websites. Hence a cyclic collection of data was
carried out to identify the ePrescribing products in implementation
and/or use in England. We compared our findings to the findings
from the academic journals search (obtained using the same
criteria as other online information sources) which did not lead to
generation of any further findings. Through this examination of
various data sources we obtained a more comprehensive and
reflexive analysis of the data than would have otherwise been
possible[18].
The overall findings included the current status of suppliers and
implementing hospitals in England as well as systems that had
once been implemented in hospitals, but had since been
discontinued. We sought to examine discontinued products in
order to have a more complete picture of the history of the market.
Finally, in this stage we performed a further analysis of the data
based on the form of solution and placement of ePrescribing
functionality within the system to generate a taxonomy of
products.
Then in stage three we performed qualitative interviews to
attempt to identify any further data sources and to obtain a
‘respondent validation’ check [18], in terms of taxonomy of
systems. In this manner, using purposive sampling we interviewed
at least one supplier or adopter hospital from each of the types
resulted from the stage two analysis. In this regard we did a ‘typical
case sampling’ [19], in which we contacted various suppliers and
user hospitals found in stage two. Our goal was to interview at least
Product Diversity and Spectrum of Choice
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one supplier or user hospital in each of the categories to test our
findings about the placement of the system in the defined category
and if necessary to refine the categories. Participant characteristics
are summarised in Table 3. The interviews were open and semi-
structured with the interview guide focusing on three main points:
(a) the nature of the ePrescribing product (this was the primary
goal), (b) the trajectory of its growth (interviews with suppliers), and
(c) strategies in procurement and implementation of the system
(interviews with adopter hospitals). The interviews were anon-
ymised and transcribed and read for checking the consistency of
findings. For the purposes of this paper, we focused on responses to
point (a) above on what the system covers (to find whether this is
just an ePrescribing system or a wider hospital information system)
and where the ePrescribing and medicine administration func-
tionalities lay within the wider system. This was done through
identification of the modules of each product and eliciting
information on, where (in which module(s)) ‘prescription or
medicine order’ and ‘administration and supply of a medicine’
(as initially identified in our definition of ePrescribing system,
above) is taking place. We also analysed data on whether the
system under examination is offering other hospital related
functionalities (e.g. Pathology or Patient Administration System)
in an integrated manner. The interviews also gave us further data
on the diversity of different interpretations and understandings of
ePrescribing systems. Finally in stage four, we contacted two
recognised experts from NHS professional domains (previously
interviewed in stages one), for a final validation of the findings.
These individuals were selected based on criterion sampling
technique [20] with the criteria of having experience in study of
ePrescribing systems in England. The experts’ inputs were used as
the final validity check for the results.
As described above, data analysis was carried out simultaneous-
ly with data collection. We analysed the results from all data
sources to create a summary of the current ePrescribing market in
England. We then interrogated our results with the aim of
categorising the products particularly in relation to the nature of
the application and its integration with other hospital information
systems. This was done by analysing the data through examination
of how they define ePrescribing, the different available modules,
and how the ePrescribing functionalities are distributed over the
system. Finally we validated our findings through presenting our
results to professional networks.
Findings
We identified over 30 relevant websites, 14 documents
collected from the programme library (including presentations
slides and vendors’ brochure), and undertook six in-depth expert
interviews.
Table 1. Criteria for Web-Searches.
System Market
Electronic Prescribing/E-Prescribing/ePrescribing/Electronic Prescription/E-Prescription/
ePrescription
NHS/NHS Hospitals/NHS Trusts
Medication Administration UK Secondary Care/English Secondary Care
HEPMA/EPMA UK Hospitals/English Hospitals/UK Trusts/English Trusts
Prescribing Software/Prescribing Application NHS Connecting for Health/NHS CFH
UK User/UK Customer/UK Adopter/English User/English Customer/
English Adopter
doi:10.1371/journal.pone.0092516.t001
Table 2. Sources of Documentary Data1.
Type of document Example Sources Nature of data collected
Conference
Publications
Publication on presentation slides from the ‘Electronic Prescribing in Hospitals - Moving Forward’
Conference, 28 February 2012, London. Conference website, ‘ePrescribing: Everything that you
want to know but were afraid to ask!’, 27 March 2012, Birmingham, http://www.crfr.ac.uk/events/
eprescribing/sponsors.html (Accessed 6, Nov. 2012)
Available products, status of
adopter hospitals, products
features and functionalities
Commercial
Material
iSoft Electronic Prescribing and Medicine Administration Brochure. JAC Medicine Management
Commercial Pack
Suppliers, products, adopter
hospitals, products features
and functionalities
Supplier Websites http://www.alert-online.com. http://www.allscripts.com. http://www.ascribe.com. http://www.
cambio.se. http://www.cerner.com. http://www.cis-healthcare.com. http://www.cse-healthcare.com.
http://www.epic.com. http://www.isofthealth.com. http://www.jac-pharmacy.co.uk. http://home.
meditech.com. http://www.medical.siemens.com. http://www.noemalife.com. http://www.
systemc.com. http://www.tpp-uk.com.
Products, products structure,
products features and
functionalities, adopter
hospitals
NHS websites www.nhs.uk. www.england.nhs.uk. www.connectingforhealth.nhs.uk. http://data.gov.uk/publisher/
nhs-connecting-for-health. http://www.srft.nhs.uk. http://www.lhch.nhs.uk. http://www.
surreyandsussex.nhs.uk. http://www.changemodel.nhs.uk.
Strategies, status of
ePrescribing in adopter
hospitals
Online Media http://www.ehi.co.uk. http://www.medicexchange.com. http://www.realwire.com. http://www.
hoise.com. http://www.tmcnet.com. http://www.prnewswire.com. http://www.tmcnet.com.
Status of products in England,
adopter hospitals
1Websites were accessed several times from 1st of November 2012 to 30th of April 2013.
doi:10.1371/journal.pone.0092516.t002
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ePrescribing Products Available in England
In analysing data collected from these sources, we found a
diverse range of ePrescribing products and functionalities in use or
available to English hospitals. Table 4 summarises our findings.
Some systems have gone through changes of name, where the
supplier name changed or where it was merged with other vendors
or acquired over the years. The name in the ‘supplier name’
column shows the name of the supplier at the time of this research.
The second column, ‘system’, indicates the name of the
ePrescribing application as mentioned on vendors’ websites. The
third column provides a descriptive narrative of the vendor and
the system extracted from publicly available, online documents.
Column four, ‘Nature of the ePrescribing Functionality’, identifies
the nature of the system functionality and its relation to wider
systems where applicable. Column five identifies the date and
country of company establishment. Finally, columns six and seven,
indicate the progression of the product in the English market and
provide some examples of customer hospitals adopting these
systems. As can be seen in Table 4, we have provided a list of
‘example customers’ at different stages of the adoption process,
ranging from the intention to implement to fully implemented and
working cases and even discontinuation.
Our findings show 17 different systems that have been available
in the English market, of which two systems have been
discontinued (and furthermore currently have no implementation
in progress); one system’s implementation has been suspended due
to its supplier being placed in administration, and one live system
has stopped being supported by its vendor. The remaining 13 have
either live implementations, are in the process of being
implemented, or have signed contracts with various hospitals.
Some, such as Epic and Ascribe are new to the English market
with a few implementations in progress while others, such as
Cerner, JAC, and MEDITECH, are already live or are currently
being implemented in a number of hospitals.
As can be seen from Table 4, not all of these systems were
developed by UK suppliers. Indeed, only half of the products were
designed and developed by UK based suppliers. The remaining
half originated from various other countries including Australia,
Germany, Italy, Portugal, Sweden, and the US. The majority of
these systems were initially designed to cater for the need of the
practices of their countries of origin and then expanded to the UK
(and elsewhere). This diversity in the background of the products
has resulted in a range of different pre-defined processes, tasks and
workflows in the system.
In addition to the hospital-wide ePrescribing systems listed in
Table 4, there are also a number of specialty products, particularly
in chemotherapy, paediatrics and mental health in use in England
and the wider UK. Amongst the most widely implemented
specialty products is the ChemoCare system developed by CIS
Oncology Limited in the UK. This system is the most widespread
electronic chemotherapy prescribing software in use across over 60
NHS hospitals. Other examples of specialty systems include ARIA
Oncology, a US system developed by Varian Medical Systems,
Oncology Patient Management administration system (OPMAS)
developed to meet the needs of chemotherapy, and RiO developed
by CSE for mental health, learning difficulty and community
services sector. The list is long, but as the aim of this study was to
focus on hospital-wide ePrescribing systems (rather than specialty
systems), we have not attempted to capture the entire range of
specialty applications. We have only named a few to show
appreciation of the existence of these products in the market.
Diversity of Products and Taxonomy of Solutions
Our analysis of the current English market reveals a diversity of
products, features and suppliers emerging over the past few years,
but limited adoption of the majority of products. We can
distinguish between systems in terms of available features. Most
systems focus on a selected range of ePrescribing features and
functionalities defined by the NHS [1]. The functionalities, which
are said to be supported by the majority of systems are: in-patient
prescribing in different areas of clinical speciality, out-patient
prescribing, discharge prescribing, availability of connection with
other hospital information system modules and applications – for
example, stock control and ordering, varying levels of medication
administration, different levels of medication screening for health
professionals, different degrees of decision support capabilities,
patient identification and grouping, and reporting features.
Apart from diversity of features and functionalities, the findings
also point to a wide array of different ePrescribing ‘modes of
supply’ (i.e. the way in which suppliers of technology make their
products available to the market) and ‘forms of solutions’ (i.e.
position of the ePrescribing systems in relation to other hospital
information systems.).
By analysing these modes we offer a typology of ePrescribing
systems into two overarching categories i.e. home-grown bespoke
products and commercial packaged applications, with the latter
category further divisible into four sub-categories: standalone
systems, modules within an integrated system, functionalities
spread over several modules, and specialty systems. While the
main difference between bespoke and packaged applications is the
mode of supply, the distinction between sub-categories within
packaged applications is defined by the forms of the solutions.
In general, our findings show a wide diversity of systems ranging
from those developed by enthusiasts within an NHS Hospital
(there are many, we have only highlighted PICS in Birmingham),
to ‘‘Commercial Off-The-Shelf’’ (COTS) systems bought from
external suppliers to be configured and used within different
hospitals. As can be seen from Table 5, COTS, also sometimes
referred to as packaged applications, fall under different categories
based on the nature of their integration and interoperability. Our
results indicate a wide range of vendor offerings, but limited
market adoption of the majority of products. In fact only one
system has more than five live hospitals using the application. The
majority of systems are having their first few customers either
recently going live or still in the process of implementation. This
suggests an immature, but potentially rapidly growing market.
Moreover, unlike more mature applications such as enterprise
resource planning systems [21], there is a lack of standard
definitions and distribution of functionalities across and within
systems. More precisely in the case of integrated systems, we can
see that some applications have a separate module that covers the
majority of features required for ePrescribing while other systems
Table 3. Participant Characteristics in Data Collection
Activities.
Participant Number Setting Type of System
1 User Type 2a System, Type 2d System
2 User Type 2b System
3 User Type 2c System
4 User Type 1 System
5 Supplier Type 2b System
6 Supplier Type 2c System
doi:10.1371/journal.pone.0092516.t003
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have these features distributed over several modules. This shows
that a consistent definition of feature and their offerings and how
these are to be supplied has not yet been achieved between the
community of vendors and adopters.
Discussion
Summary of the Main Findings
The ePrescribing market is still in its early stages in England; it
is however rapidly expanding and changing in response to the
increasing demand. There is evidence of a wide range of products
entering (and sometimes leaving) the English NHS over recent
years. These systems have been developed in various forms by
different national and international suppliers. This diversity of
choice has led to varied strategies in selection of the products in the
secondary health sector in England. Hospitals need to make
important decisions in relation to both the distributor and the
choice of system. This recent rapid expansion in the UK market
can to a large extent be explained by the recent demise of
England’s National Programme for Information Technology,
which had resulted in central government contracting with a
limited number of suppliers and had as a consequence led to non-
preferred providers abandoning the UK market [22]. With such
major recent fluctuations in the market, it is we believe important
for NHS hospitals to have access to independent data on the range
of available systems and insights into their functionality, interop-
erability potential and costs in order to inform the decision making
process.
This work provides an overview of the current situation of
ePrescribing applications in English hospitals and then categorises
them into five different types in terms of modes of supply and
forms of solution. In so doing, this study echoes the findings of our
two earlier descriptive surveys of ePrescribing implementation in
English hospitals [6,12] by highlighting the move from adoption of
bespoke applications to packaged systems.
Implications of the Diversity on the Choice
The study shows that the choice between these categories has a
number of potentially significant implications for the adopting
hospitals. They include different degrees of integration and
interoperability, variations in time and cost of implementation
for adopting hospitals, and various degrees of alignment between
the processes supported by products and hospital practices.
First of all there are important issues in need of attention around
integration and interoperability of different applications. As
explained earlier, ePrescribing systems maybe modules within
other hospital information systems (such as Electronic Health
Record - EHR systems), they maybe functionalities spread over
several other modules, or they could be standalone applications
with limited or no integration with other hospital information
systems. Earlier research suggested that investing in increased
integration is likely to be associated with fuller realisation of
operational benefits [23]. Such benefits include synchronisation
between hospital activities, integration of human resources and
better efficiency and productivity. Integrated systems make access
to information available at any place in the hospital. Instead lack
of integration, can lead to multiple data entry points which can
result in problems such as increased potential of error and greater
operating costs.
Such integrations tend to be easier to achieve through
integrated packaged applications rather than bespoke systems.
As can be seen in the case of PICS (implementation started in
1998, the majority of wards live in 2006), the implementation time
for bespoke applications tends to be much longer than packaged
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applications. It is something of a paradox that, due to frequent
elaboration and alterations of requirements, addition of new
functionalities and drift of the system and lack of adherence to
standards and pre-defined practices, the implementation of
bespoke systems tends to be more time consuming and require
more effort than packaged systems [24–26]. As well as being time
consuming, due to the need for in house development and
maintenance teams, they are also more costly [27–29]. The
costliness of such systems, has led to a move away from bespoke
developments to adopting packaged applications.
Despite their benefits, packaged applications have faced a
number of critiques by researchers. The main challenge widely
discussed is the lack of supplier-user proximity [30]. This issue,
which is in fact associated with all types of packaged systems leads
to what some refer to as ‘misalignment’ or ‘misfit’ between a
specific user organisation’s needs and the standard application’s
generic functionalities [31–32]. This is in contrast to the offerings
of bespoke systems in which the application is designed to meet the
exact need of the individual organisation.
As noted above, packaged applications tend to be less costly and
less time consuming than bespoke developments. Standalone
applications also tend to be cheaper to procure and quicker to
implement. These reasons have led to implementation of
standalone systems by a larger number of hospitals. In this
manner these hospitals have perhaps opted to achieve short term
benefits while investing less in the product. Such standalone
systems tend to be unconnected in nature and simple to configure
[26]. However integration and interoperability of standalone
solutions with wider systems may be costly and difficult to achieve
following initial implementation [26–27].
A combination of more or less conflicting factors underpinned
the diversity of choice in the English hospitals. They include
different system functionalities and the extent to which they match
the needs of English hospitals, differing degrees of integration and
interoperability with other hospital information systems, cost of
implementation, and time and effort required for adoption of the
system.
Considering the Findings in Light of Existing ePrescribing
Market Studies
We have investigated the English ePrescribing market and
revealed a wide range of offerings in England. To our knowledge,
there are currently no similar studies that address the broad scope
of ePrescribing systems in the English market. Our study, which
confirms and extends our earlier findings from two questionnaire
studies of the implementation and adoption of ePrescribing
systems in English hospital [6], [12], may be the first to examine
these systems and their market penetration.
A report by eHealth Initiative [33] suggests a model based on
the sophistication of the system through what is described as
‘graduated levels’ of ePrescribing systems. The paper distinguishes
very low level of ‘basic electronic references’ (Level 1 – i.e. systems
with drug and formulary information but not used in prescribing),
and moves up by defining ‘standalone prescription writers’ (Level
2 – i.e. creation of prescription with not long-term data about
patients), systems with support of patient data (Level 3), systems
with medication management (Level 4), systems with connectivity
to other applications such as pharmacy (Level 5), and finally
systems integrated with Electronic Medical Records (EMR – a
subcategory of electronic health records) (Level 6). Sheikh et al.
takes this model one step further and categorises these six levels
into 3 types: standalone system (combination of levels 1 and 2),
systems integrated with EHR (combination of levels 3, 4, and 5),
and systems integrated with EMR (level 6). In doing so, they show
that these integrations have a direct effect on the decision support
functionalities and hence as we move up the levels, with higher
integration, we are able to observe more advanced decision
support functionalities. Further to this, the NHS recently
published a report [34], which shows a similar view on the
interoperability of various available systems. Our results confirm
Table 5. Typology of EPRESCRIBING systems.
System Type Description Example
Type 1: Bespoke
Systems
Home-grown systems developed to meet the particular requirements of a single
hospital. During the design process of these systems the user and vendor are directly
connected and the aim is to solve the particular needs of the user organisation.
PICS
Type 2: Packaged
Application
Applications designed with the aim of catering for the needs of various organisations. They tend to cover the ‘generic’ needs of adopter
hospitals. Hence a standard system is designed to be implemented in different hospitals. These systems are configured (or
parameterised) to meet particular needs of each hospital.
Type 2a: Standalone
systems
In this case the ePrescribing system is a separate application, not connected to wider
hospital information system. Particular interfaces are required to link such applications
to other systems.
JAC
Type 2b: Modules
within an integrated
system
A single module that performs various functionalities required for prescribing and
administration of medicine and works as a part of a larger health information system.
In such cases the ePrescribing module can be implemented as a whole unit at
different points of time. Integrated systems tend to have more advanced decision
support functionalities.
Cerner, Lorenzo
Type 2c: Functionalities
spread over several
modules
Similar to the above case, this type of system also integrates into a larger health
information system. However it differs from 2b in that the ePrescribing functionalities
are not compiled into a single module; rather they are performed by multiple
integrated modules. Hence to have the entire functionalities, various modules must
be implemented. Integrated systems tend to have more advanced decision support
functionalities.
Magic, EpicCare
Type 2d: Specialty
systems
These systems are designed to meet the particular needs of a specialty in health care.
Similar to the above cases they are designed as standard packages, but with special
features to cater for the particularities of that specialty care. The specialty systems may
be designed as standalone applications or modules within an integrated system.
ChemoCare, ARIA Oncology
doi:10.1371/journal.pone.0092516.t005
Product Diversity and Spectrum of Choice
PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e92516
the existence of these levels of sophistication and interoperability
with different hospital information systems, but we suggest that this
categorisation is a partial view of the existing systems as it does not
show different modes of supply and the potential of having the
features spread over the wider integrated system. In this way our
taxonomy offers a more comprehensive view of ePrescribing
systems supply.
Strengths and Limitations
As far as we are aware, this is the first in-depth empirical study
of the English ePrescribing market. Furthermore, we are also not
aware of any similar studies which present a detailed picture of the
market in other countries. Our results are not only usable as a
source of input to English and more broadly UK hospitals, but
they can also be used as a basis for comparison to the market in
other countries.
Out long-track of studying IT in healthcare, together with our
prior work on ePrescribing in the NHS on which this study builds
and our multidisciplinary knowledge and experience in the study
of enterprise information systems in various sectors enabled us to
relate our findings with the wider research agenda on information
systems in organisations. This enabled us to draw on conclusions
not only with respect to findings in health information system
research but also to discuss the matters in light of the existing
literature on other types of enterprise applications.
There are some limitations to this study, including a partial
insight into the detailed functionalities and offerings of these highly
complex software products compounded by incomplete public
availability of information about products, reflecting commercial
sensitivities. The properties of such highly complex software
products cannot simply be verified by visual inspection, and only
become fully apparent as they are implemented and used within
specific organisational settings [26]. This limits the scope for
detailed analysis and comparison of the features.
We used an online document search method followed by
interviews in collecting the data for this study. This was done to
show a snapshot of the English ePrescribing market and categorise
the findings into meaningful groups. However due to the scoping
nature of the searches and the limited number of expert interviews,
care needs to be taken in interpreting our findings. Furthermore,
as this work is grounded in the context of NHS England careful
considerations are required to generalise these findings to non-UK
settings and contexts.
A further difficulty was examination of a constantly changing
market. As the aim of this research was to draw a picture of the
current ePrescribing market in England, we tried to convey the
most up to date findings as of the date of this research. However,
product features and their adoption experience are both changing
rapidly. This study needs to be updated continuously to offer a
complete view on changes in the market.
Conclusions and Ways Forward
The ePrescribing market in England is going through multiple
cycles of change. Many new products are entering the market
while existing technologies are undergoing rapid change. More-
over, there is no uniform conception of ePrescribing systems.
Instead our observations showed a fluctuating definition, which is
evolving as the technology and its usage are being shaped and
reshaped. Hence, there is a double immaturity in the market, one
in relation to the conception of the ePrescribing as a result of
uncoordinated and sometimes inconsistent user needs and the
other with regard to the uneven growth of the systems with
differing modes of supply, form of solutions and functionalities. As
the market becomes more mature, we would expect to see more
standard definitions and interpretations of ePrescribing systems
and their functionalities. Also, rather than limited adoption of a
wide range of systems, we would expect to see higher rates of
adoption of a limited number of ePrescribing systems. Such a
market, with larger number of live implementations and more
mature products, would facilitate decision making for procurement
of desired products.
We present these mixed methods descriptive findings as a
starting point for understanding the wide range of choices facing
hospitals – between different ePrescribing categories and between
different products within these categories – in order to facilitate
better decision making. The wide range of available offerings, yet
with few uptakes, reflects the immaturity of a market which is still
undergoing rapid changes – a fact which will in turn necessitate
frequent updates to the findings of this paper. Further work is also
required to expand the current study in terms of increasing the
level of detail regarding the functionality and features of the
diverse range of applications. We also suggest that these
parameters could be incorporated into appropriate assessment
tools for assisting the process of selection of products.
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